Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

Ähnliche Einträge

• Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies
  von: Agrawal, Sudhir, et al.
  Veröffentlicht: (1997)
• Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration
  von: Wang, Hui, et al.
  Veröffentlicht: (1999)
• Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
  von: Chen, Lihong, et al.
  Veröffentlicht: (1998)
• Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
  von: Tortora, Giampaolo, et al.
  Veröffentlicht: (1997)
• p53 Antisense Oligonucleotide Inhibits Growth of Human Colon Tumor and Normal Cell Lines
  von: Hirota, Yasuhide, et al.
  Veröffentlicht: (1996)